BirchBioMed

Millions suffer with few available treatments for their debilitating medical issues.

BirchBioMed is a global, cutting-edge clinical-stage biopharmaceutical company headquartered in Canada. The company is dedicated to pioneering innovative treatments for organ fibrosis, scarring (fibrosis) and associated skin disorders, as well as specific autoimmune disorders, including Type 1 Diabetes (T1D) and Alopecia Areata (AA).

our focus

Develop life-changing treatments to solve unmet medical needs.

BirchBioMed leads the way in biopharmaceuticals, developing advanced treatments for fibrosis and subsets of specific autoimmune disorders. Our focus is on Kynurenic Acid (KynA), a compound with antifibrogenic properties, used in topical, systemic, and cutting-edge therapies to reshape fibrosis treatments and, in combination with antigen-presenting cell (APC) therapy, to address certain autoimmune disorders.

Explore our groundbreaking approach to improving patient outcomes.

The Team

A deeply experienced team
of healthcare leaders.

At BirchBioMed, our team of world-class scientists, researchers, and business professionals drives the development of groundbreaking therapies. Together, we are shaping the future of healthcare with passion and precision. Get to know the experts behind our success.

Partnering

Empower our mission to help millions.

At BirchBioMed, we believe in the power of collaboration to advance medical innovation and enhance patient care. Our strategic partnering opportunities are designed to forge alliances that leverage our cutting-edge research and development in the field of biopharmaceuticals.

investors

Invest in the Future of Healthcare Innovation

Approved for crowdfunding (Reg A+) and prepared to be publicly listed in a few months, we are positioned to potentially transform the future of healthcare in major therapeutic indications. With a Total Addressable Market (TAM) of $96.9B, our innovative therapies target high-impact diseases, offering significant growth potential for investors.